2018
DOI: 10.1126/scitranslmed.aan5488
|View full text |Cite
|
Sign up to set email alerts
|

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

Abstract: Antibodies targeting immune checkpoints are emerging as potent and viable cancer therapies, but not all patients respond to these as single agents. Concurrently targeting additional immunosuppressive pathways is a promising approach to enhance immune checkpoint blockade, and bifunctional molecules designed to target two pathways simultaneously may provide a strategic advantage over the combination of two single agents. M7824 (MSB0011359C) is a bifunctional fusion protein composed of a monoclonal antibody again… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

11
435
1

Year Published

2018
2018
2024
2024

Publication Types

Select...
7
1
1

Relationship

1
8

Authors

Journals

citations
Cited by 424 publications
(469 citation statements)
references
References 103 publications
11
435
1
Order By: Relevance
“…Recent studies revealed that co-administration of anti-PD-L1 antibody and TGF-β inhibitor (Galunisertib or anti-TGF-β antibody) showed high anti-tumor immunity and tumor regression [227,228]. Moreover, enhanced anti-tumor activities could be observed by using bifunctional fusion proteins containing the PD-L1 (or CTLA-4) antibody and the TβRII extracellular domain [215,229].…”
Section: Application Of Garp For Cancer Immunotherapymentioning
confidence: 99%
“…Recent studies revealed that co-administration of anti-PD-L1 antibody and TGF-β inhibitor (Galunisertib or anti-TGF-β antibody) showed high anti-tumor immunity and tumor regression [227,228]. Moreover, enhanced anti-tumor activities could be observed by using bifunctional fusion proteins containing the PD-L1 (or CTLA-4) antibody and the TβRII extracellular domain [215,229].…”
Section: Application Of Garp For Cancer Immunotherapymentioning
confidence: 99%
“…The selective copy number gains for these immune genes are likely to be related to tumor-immune system interactions (Figure 1c). Recently, a molecule simultaneously inhibiting TGFB2 and PD-L1 is reported and showed its high efficacy (Lan et al, 2018;Strauss et al, 2018).…”
Section: Resultsmentioning
confidence: 99%
“…Inhibition of TGF‐beta in the tumor microenvironment may enhance the activity of anti‐PD1/PD‐L1. Bintrafusp alfa (M7824) is a bifunctional fusion protein targeting both PD‐L1 and TGF‐beta . In a phase I study (Strauss J et al, American Academy of Cancer Research annual meeting 2019, CT075) (Table ), 43 patients with HPV‐associated malignancies were enrolled, of whom 14 had HNSCC.…”
Section: Combination Therapy For Hnsccmentioning
confidence: 99%
“…Bintrafusp alfa (M7824) is a bifunctional fusion protein targeting both PD-L1 and TGF-beta. 50 In a phase I study (Strauss J et al, American Academy of Cancer Research annual meeting 2019, CT075) (…”
Section: Tgf-beta/pd-l1 Bifunctional Fusion Protein: Bintrafusp Alfmentioning
confidence: 99%